Residual Corticosteroid Production in Autoimmune Addison Disease.

Adrenal failure Autoimmune Addison disease adrenal steroids cortisol primary adrenal insufficiency residual function

Journal

The Journal of clinical endocrinology and metabolism
ISSN: 1945-7197
Titre abrégé: J Clin Endocrinol Metab
Pays: United States
ID NLM: 0375362

Informations de publication

Date de publication:
01 07 2020
Historique:
received: 31 01 2020
accepted: 07 05 2020
pubmed: 12 5 2020
medline: 4 2 2021
entrez: 12 5 2020
Statut: ppublish

Résumé

Contrary to current dogma, growing evidence suggests that some patients with autoimmune Addison disease (AAD) produce corticosteroids even years after diagnosis. To determine frequencies and clinical features of residual corticosteroid production in patients with AAD. Two-staged, cross-sectional clinical study in 17 centers (Norway, Sweden, and Germany). Residual glucocorticoid (GC) production was defined as quantifiable serum cortisol and 11-deoxycortisol and residual mineralocorticoid (MC) production as quantifiable serum aldosterone and corticosterone after > 18 hours of medication fasting. Corticosteroids were analyzed by liquid chromatography-tandem mass spectrometry. Clinical variables included frequency of adrenal crises and quality of life. Peak cortisol response was evaluated by a standard 250 µg cosyntropin test. Fifty-eight (30.2%) of 192 patients had residual GC production, more common in men (n = 33; P < 0.002) and in shorter disease duration (median 6 [0-44] vs 13 [0-53] years; P < 0.001). Residual MC production was found in 26 (13.5%) patients and associated with shorter disease duration (median 5.5 [0.5-26.0] vs 13 [0-53] years; P < 0.004), lower fludrocortisone replacement dosage (median 0.075 [0.050-0.120] vs 0.100 [0.028-0.300] mg; P < 0.005), and higher plasma renin concentration (median 179 [22-915] vs 47.5 [0.6-658.0] mU/L; P < 0.001). There was no significant association between residual production and frequency of adrenal crises or quality of life. None had a normal cosyntropin response, but peak cortisol strongly correlated with unstimulated cortisol (r = 0.989; P < 0.001) and plasma adrenocorticotropic hormone (ACTH; r = -0.487; P < 0.001). In established AAD, one-third of the patients still produce GCs even decades after diagnosis. Residual production is more common in men and in patients with shorter disease duration but is not associated with adrenal crises or quality of life.

Identifiants

pubmed: 32392298
pii: 5835888
doi: 10.1210/clinem/dgaa256
pmc: PMC7274491
pii:
doi:

Substances chimiques

Adrenal Cortex Hormones 0
Cosyntropin 16960-16-0

Banques de données

ClinicalTrials.gov
['NCT03793114']

Types de publication

Clinical Trial Journal Article Multicenter Study Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

© Endocrine Society 2020.

Références

N Engl J Med. 2004 May 13;350(20):2068-79
pubmed: 15141045
J Clin Endocrinol Metab. 2012 Oct;97(10):E1927-32
pubmed: 22767640
Health Econ. 1993 Oct;2(3):217-27
pubmed: 8275167
Endocr Connect. 2018 May;7(5):617-629
pubmed: 29622661
Clin Chim Acta. 2017 Jul;470:115-124
pubmed: 28479316
J Clin Endocrinol Metab. 2018 Apr 1;103(4):1696-1703
pubmed: 29452421
Clin Endocrinol (Oxf). 2002 Jun;56(6):787-91
pubmed: 12072049
J Urol. 2018 May;199(5):1357-1358
pubmed: 29428631
Endocr Rev. 2015 Oct;36(5):564-91
pubmed: 26357922
J Steroid Biochem Mol Biol. 2020 Apr;198:105553
pubmed: 31778802
J Clin Endocrinol Metab. 2020 Apr 1;105(4):
pubmed: 31863094
Endocr Connect. 2013 Jun 14;2(3):125-136
pubmed: 23825158
Clin Endocrinol (Oxf). 2019 Sep;91(3):383-390
pubmed: 31059146
Clin Endocrinol (Oxf). 2011 Apr;74(4):434-7
pubmed: 21114513
J Clin Endocrinol Metab. 2012 Feb;97(2):568-76
pubmed: 22090270
Clin Endocrinol (Oxf). 2013 Jun;78(6):831-7
pubmed: 23134110
J Clin Endocrinol Metab. 2017 Feb 1;102(2):379-389
pubmed: 27870550
Endocr Rev. 2011 Feb;32(1):81-151
pubmed: 21051590
Eur J Endocrinol. 2010 Mar;162(3):597-602
pubmed: 19955259
J Clin Endocrinol Metab. 2014 Jan;99(1):111-8
pubmed: 24170102
Ann N Y Acad Sci. 2006 Nov;1083:165-84
pubmed: 17148739
J Clin Endocrinol Metab. 2009 Dec;94(12):4882-90
pubmed: 19858318
Nat Rev Immunol. 2016 Oct;16(10):626-38
pubmed: 27546235
Endocr Rev. 2019 Aug 1;40(4):973-987
pubmed: 30882882
J Intern Med. 2014 Feb;275(2):104-15
pubmed: 24330030
Cell Stem Cell. 2019 Aug 1;25(2):290-296.e2
pubmed: 31104943
J Clin Endocrinol Metab. 2020 Feb 1;105(2):
pubmed: 31532828
J Clin Endocrinol Metab. 2020 Jan 1;105(1):
pubmed: 31613957
Diabetologia. 2019 Apr;62(4):567-577
pubmed: 30767048
Clin Endocrinol (Oxf). 2018 Jul;89(1):30-35
pubmed: 29682773
J Clin Endocrinol Metab. 2019 Jun 1;104(6):2031-2040
pubmed: 30608542

Auteurs

Åse Bjorvatn Sævik (ÅB)

Department of Clinical Science, University of Bergen, Norway.
K.G. Jebsen Center for Autoimmune Disorders, University of Bergen, Bergen, Norway.

Anna-Karin Åkerman (AK)

Department of Medicine, Örebro University Hospital, Örebro, Sweden.
Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden.

Paal Methlie (P)

Department of Clinical Science, University of Bergen, Norway.
K.G. Jebsen Center for Autoimmune Disorders, University of Bergen, Bergen, Norway.
Department of Medicine, Haukeland University Hospital, Bergen, Norway.

Marcus Quinkler (M)

Endocrinology in Charlottenburg, Berlin, Germany.

Anders Palmstrøm Jørgensen (AP)

Department of Endocrinology, Oslo University Hospital, Oslo, Norway.

Charlotte Höybye (C)

Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden.
Department of Endocrinology, Metabolism and Diabetes, Karolinska University Hospital, Stockholm, Sweden.

Aleksandra J Debowska (AJ)

Department of Medicine, Vestfold Hospital Trust, Tønsberg, Norway.

Bjørn Gunnar Nedrebø (BG)

Department of Clinical Science, University of Bergen, Norway.
Department of Internal Medicine, Haugesund Hospital, Haugesund, Norway.

Anne Lise Dahle (AL)

Department of Internal Medicine, Haugesund Hospital, Haugesund, Norway.

Siri Carlsen (S)

Department of Endocrinology, Stavanger University Hospital, Stavanger, Norway.

Aneta Tomkowicz (A)

Department of Medicine, Sørlandet Hospital, Kristiansand, Norway.

Stina Therese Sollid (ST)

Department of Medicine, Drammen Hospital, Vestre Viken Health Trust, Drammen, Norway.

Ingrid Nermoen (I)

Department of Endocrinology, Akershus University Hospital, Lørenskog, Norway.

Kaja Grønning (K)

Department of Endocrinology, Akershus University Hospital, Lørenskog, Norway.

Per Dahlqvist (P)

Department of Public Health and Clinical Medicine, Umeå University, Umeå, Sweden.

Guri Grimnes (G)

Division of Internal Medicine, University Hospital of North Norway, Tromsø, Norway.
Tromsø Endocrine Research Group, Department of Clinical Medicine, UiT the Arctic University of Norway, Tromsø, Norway.

Jakob Skov (J)

Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden.

Trine Finnes (T)

Section of Endocrinology, Innlandet Hospital Trust, Hamar, Norway.

Susanna F Valland (SF)

Section of Endocrinology, Innlandet Hospital Trust, Hamar, Norway.

Jeanette Wahlberg (J)

Department of Endocrinology and Department of Health, Medicine and Caring Sciences, Linköping University, Linköping, Sweden.

Synnøve Emblem Holte (SE)

Department of Medicine, Sørlandet Hospital, Arendal, Norway.

Katerina Simunkova (K)

Department of Clinical Science, University of Bergen, Norway.

Olle Kämpe (O)

K.G. Jebsen Center for Autoimmune Disorders, University of Bergen, Bergen, Norway.
Department of Endocrinology, Metabolism and Diabetes, Karolinska University Hospital, Stockholm, Sweden.
Department of Medicine (Solna), Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden.

Eystein Sverre Husebye (ES)

Department of Clinical Science, University of Bergen, Norway.
K.G. Jebsen Center for Autoimmune Disorders, University of Bergen, Bergen, Norway.
Department of Medicine, Haukeland University Hospital, Bergen, Norway.
Department of Medicine (Solna), Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden.

Sophie Bensing (S)

Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden.
Department of Endocrinology, Metabolism and Diabetes, Karolinska University Hospital, Stockholm, Sweden.

Marianne Øksnes (M)

Department of Clinical Science, University of Bergen, Norway.
K.G. Jebsen Center for Autoimmune Disorders, University of Bergen, Bergen, Norway.
Department of Medicine, Haukeland University Hospital, Bergen, Norway.
Department of Medicine (Solna), Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH